Patients using Novorapid fast acting insulin are being advised to switch to Trurapi which is a biosimilar medication made by Sanofi. It has been tested to ensure that is it equally effective and safe.
The NHS is under great financial pressure and it is extremely important that we make sure we spend public money carefully, using the better value choices, so that the NHS can afford the best care for patients. Trurapi is much better value for the NHS to prescribe. Local diabetes experts have agreed that patients who are currently being treated with Novorapid should be switched to Trurapi.
We will be sending letters to patients advising of the switch. We would recommend using up your remaining Novorapid before starting to use your new insulin. The dose you should use of Trurapi is the same as you would have given with Novorapid.
There are some situations in which you might not want to switch, for example:
If you are not happy for your medication to be changed or one of the above situations applies to you then there are instructions on the paperwork to follow to let us know.